Salute e Benessere
Sobi Q3 2024 report: Strong growth and significant pipeline momentum
* The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant®, Vonjo® and Zynlonta®, and royalty on Sanofi's sales of Altuviiio® and Beyfortus.
Investors, analysts, and the media are invited to a conference call on the same day at 14:00 CEST, 13:00 BST , and 08:00 EDT . The call will include a presentation of the results and a Q&A session.
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.
To participate in the conference call, please use the following dial-in details:
Sweden : +46 8 5051 0031
United Kingdom : +44 207 107 06 13
United States : +1 631 570 56 13
For other countries, please find the details here .
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe , North America , the Middle East , Asia and Australia . In 2023, revenue amounted to SEK 22.1 billion . Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn .
For details on how to contact the Sobi Investor Relations Team, please click here . For Sobi Media contacts, click here .
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CEST on 24 October 2024 .
Gerard Tobin
Head of Investor Relations
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content: https://www.prnewswire.co.uk/news-releases/sobi-q3-2024-report-strong-growth-and-significant-pipeline-momentum-302285671.html